IPO registrations (S-1, F-1) · Registrants
Passage BIO, Inc.
- SEC CIK
- 1787297 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2020-02-03, last 2021-01-19; 2 initial registrations, 2 amendments
- Outcome
- Final prospectus filed 2020-02-28; declared effective 2020-02-27
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, Philadelphia, PA 19103
- EIN
- 82-2729751
- Ticker
- PASG (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Passage BIO, Inc. on the corporate pages
Offering terms
- Proposed price range
- $16.00–$18.00 per share (S-1/A filed 2020-02-27)
- Final price
- $18.00 per share, within the range (424B4 filed 2020-02-28, an initial public offering)
- Shares sold
- 12,000,000
- Gross proceeds
- $216,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol PASG
- Lead underwriters
- J.P. Morgan; Goldman Sachs; Cowen
- Syndicate
- Chardan
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Passage Bio, Inc. Fuzzy (name and state)
- Form D issuer: Passage BIO, Inc. EXACT (CIK (EXACT))
- SEC filer: Passage BIO, Inc. EXACT (CIK (EXACT))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-02-03 | S-1 | S-1 (registration) | Passage BIO, Inc. | 0001047469-20-000652 ↗ |
| 2020-02-18 | S-1/A | S-1/A (amendment) | Passage BIO, Inc. | 0001047469-20-000894 ↗ |
| 2020-02-27 | S-1/A | S-1/A (amendment) | Passage BIO, Inc. | 0001047469-20-001071 ↗ |
| 2020-02-27 | S-1MEF | S-1MEF (added securities) | Passage BIO, Inc. | 0001047469-20-001096 ↗ |
| 2020-02-27 | EFFECT | EFFECT (declared effective) | Passage BIO, Inc. | 9999999995-20-000432 ↗ |
| 2020-02-28 | 424B4 | 424B4 (final prospectus) | Passage BIO, Inc. | 0001047469-20-001117 ↗ |
| 2021-01-19 | S-1 | S-1 (registration) | Passage BIO, Inc. | 0001104659-21-005296 ↗ |
| 2021-01-21 | EFFECT | EFFECT (declared effective) | Passage BIO, Inc. | 9999999995-21-000233 ↗ |
| 2021-01-22 | 424B1 | 424B1 (final prospectus) | Passage BIO, Inc. | 0001104659-21-006683 ↗ |
| 2022-04-14 | EFFECT | EFFECT (declared effective) | Passage BIO, Inc. | 9999999995-22-000975 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-02-27 | S-1/A | registration statement | $16.00–$18.00 | 10,000,000 | - | Nasdaq PASG | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2020-02-28 | 424B4 | final prospectus | $18.00 | 12,000,000 | $216,000,000 | Nasdaq PASG | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Cale Edgar B. | Officer | GC and Corporate Secretary; GC & Corporate Secretary; GC & CORPORATE SECRETARY; Interim CEO, GC & Corp. Sec. | 13 | 2020–2025 | |
| Countouriotis Athena | Director | 10 | 2020–2026 | ||
| FHMLS IX, L.L.C. | TenPercentOwner | 2 | 2020 | ||
| FHMLS IX, L.P. | TenPercentOwner | 2 | 2020 | ||
| Fotopoulos Alexandros | Officer | Chief Technical Officer | 11 | 2020–2023 | |
| Frazier Life Sciences IX, L.P. | TenPercentOwner | 2 | 2020 | ||
| Goldsmith Bruce A | Director,Officer | CEO and President | 7 | 2020–2022 | |
| Heron Patrick J | Director,TenPercentOwner | 3 | 2020 | ||
| Islam Saqib | Director | 8 | 2020–2025 | ||
| Kapadia Sandip | Director | 10 | 2020–2026 | ||
| Morris Richard Steven | Officer | Chief Financial Officer | 5 | 2020–2021 | |
| ORBIMED ADVISORS LLC | TenPercentOwner | 18 | 2020–2025 | ||
| OrbiMed Capital GP VII LLC | TenPercentOwner | 18 | 2020–2025 | ||
| Quigley Jill M. | Officer | Chief Operating Officer | 7 | 2020–2021 | |
| Ratcliffe Liam | Director | 6 | 2020–2021 | ||
| Romano Gary | Officer | Chief Medical Officer | 4 | 2020–2021 | |
| SQUINTO STEPHEN P | Director,Officer | Head of Research and Dev | 2 | 2020 | |
| Topper James N | TenPercentOwner | 2 | 2020 | ||
| Versant Vantage I GP-GP, LLC | TenPercentOwner | 2 | 2020 | ||
| Versant Vantage I GP, L.P. | TenPercentOwner | 2 | 2020 | ||
| Versant Vantage I, L.P. | TenPercentOwner | 2 | 2020 | ||
| Versant Venture Capital VI, L.P. | TenPercentOwner | 2 | 2020 | ||
| Versant Ventures VI GP-GP, LLC | TenPercentOwner | 2 | 2020 | ||
| Versant Ventures VI GP, L.P. | TenPercentOwner | 2 | 2020 | ||
| Woiwode Thomas | Director; Director,TenPercentOwner | 8 | 2020–2023 | ||
| Yamada Tadataka | Director | 4 | 2020–2021 | ||
| GOWEN MAXINE | Director | 9 | 2021–2026 | ||
| Salinas Eliseo Oreste | Officer | Chief Res. & Develop Officer | 3 | 2021–2022 | |
| Porter Derrell | Director | 7 | 2021–2026 | ||
| Burkavage Brian | Officer | Controller | 1 | 2021 | |
| Toernsen Monika Maria | Officer | Chief Commercial Officer | 5 | 2021–2022 | |
| King Simona | Officer | Chief Financial Officer | 9 | 2021–2023 | |
| Forman Mark S | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 8 | 2022–2024 | |
| Kamarck Michael E. | Director | 3 | 2022–2023 | ||
| Chou William | Director,Officer | Chief Executive Officer; President and CEO; PRESIDENT AND CEO | 8 | 2022–2026 | |
| Borthwick Kathleen | Officer | CFO; SVP, Interim CFO; SVP, INTERIM CFO | 10 | 2023–2026 | |
| Sondhi Dolan | Director | 5 | 2023–2026 | ||
| Lynx1 Capital Management LP | TenPercentOwner | 6 | 2024–2026 | ||
| Nichols Weston | TenPercentOwner | 6 | 2024–2026 | ||
| Kassberg Thomas Richard | Director | 4 | 2024–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-09-06 | Passage BIO, Inc. | Other Health Care | $110,000,000 | $109,999,974 | 15 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Passage Bio, Inc. | PA | State business registries | name and state |
| Form D issuer | Passage BIO, Inc. | PA | Form D private offerings | CIK (EXACT) |
| SEC filer | Passage BIO, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Passage Bio, Inc. | PA | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), PA first:
- APOLLON INC PA
- Aevi Genomic Medicine, LLC PA
- Ocugen, Inc. PA
- Spark Therapeutics, Inc. PA
- Krystal Biotech, Inc. PA
- Cabaletta Bio, Inc. PA
- Century Therapeutics, Inc. PA
- Aphton CORP PA
- Aceragen, Inc. PA
- GENAERA CORP PA
In other datasets, the same topic (Health) in PA:
- Nonprofit: 445 FOUNDATION (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health